News Release

Statins could increase or decrease osteoporosis risk -- the dosage makes the difference

A study by the the Medical University of Vienna and the Complexity Science Hub Vienna shows for the first time a connection between the dosage of cholesterol-lowering drugs and the diagnosis of osteoporosis

Peer-Reviewed Publication

Complexity Science Hub Vienna

Statins & Osteoporosis

image: Dosage dependency of the statin--osteoporosis association in three frequently prescribed statins: A low dosage of simvastatin and rosuvastatin can be related to decreased osteoporosis risks, as indicated by the bars left of the cut-off line of 1. The probability for a diagnosis with osteoporosis clearly increases in all three statins with dosages of 40 milligrams and above. view more 

Credit: M. Leutner, C. Matzhold, L. Bellach, C. Deischinger, J. Harreiter, S. Thurner, P. Klimek, A. Kautzky-Willer

[Vienna, September 30, 2019] At low doses, statins could protect against bone resorption. But the higher the dosage of cholesterol-lowering drugs, the greater the probability of osteoporosis, an analysis of millions of patient data by the Complexity Science Hub Vienna shows. The paper appears in the current issue of the top journal Annals of the Rheumatic Diseases.

Statins are among the most prescribed drugs worldwide. They lower high cholesterol and have been shown to reduce the risk of cardiovascular diseases. Less well-researched are complications in connection with the intake of statins, such as a possible influence on pathological bone resorption (osteoporosis).

Michael Leutner from the Clinical Department of Endocrinology and Metabolism at the Medical University of Vienna (MedUni), and first author of the study, explains the likely pathway. "Statins inhibit the synthesis of cholesterol from the liver. This lowers blood cholesterol. However, cholesterol is crucially important for many processes in the body." Among other things, it is a basic building block for the production of sex hormones such as estradiol and testosterone.

"We know that low concentrations of sex hormones—especially the drop in estrogen levels during menopause—are the main cause for the increase of osteoporosis in women," explains Alexandra Kautzky-Willer, an expert in gender medicine and endocrinology, and head of the MedUni team. "There is a similar relationship between bone density and testosterone. We were interested in whether the inhibition of cholesterol production by statins has an effect on bone formation and whether there could be a dose-response relationship."

The higher the dosage, the stronger the effect

For their investigation, the research team used Big Data. "We had access to the health data of more than 7.9 million Austrians from 2006 and 2007," mentions Caspar Matzhold from the Complexity Science Hub Vienna. Matzhold carried out the processing and statistical analysis of the data. "We filtered out from this big data set those who regularly took statins for at least one year," he adds. Matzhold also calculated the daily dosage of statins and formed different dosage groups.

In a further step, the interdisciplinary team filtered out osteoporosis diagnoses. They found a correlation between the dosage of statins and the frequency of osteoporosis.

"In the lower dose groups, there were fewer osteoporosis cases than expected," Kautzky-Willer points out. At doses up to 10 milligrams of the statins lovastatin, pravastatin, simvastatin or rosuvastatin, the scientists found fewer osteoporosis diagnoses compared to patients without statin therapy. "With doses of 20 milligrams and more, however, the tide seems to turn. We found more osteoporosis cases in patients treated with simvastatin, atorvastatin and rosuvastatin than expected," explains Kautzky-Willer. The higher the dosage, the stronger the effect.

The trend also persisted after Matzhold had controlled the data for osteoporosis risk factors such as age, overweight, and other pre-existing conditions. The correlation was seen in both sexes.

Big insights through Big Data

"In earlier joint studies we saw how helpful large data sets can be to examine open medical questions," says Peter Klimek, leader of the data analysis team at the Complexity Science Hub Vienna and at the Medical University of Vienna. "The combination of medical expertise with our knowledge in big data analysis makes completely new insights possible." According to Klimek, the newly discovered correlation between statin therapy and osteoporosis risk should now be investigated in clinical studies.

"With such results, we are coming closer to a truly personalized and individualized medicine," maintains Kautzky-Willer. "We can now advise high-risk osteoporosis patients undergoing statin therapy to have their bone metabolism regularly monitored."


M. Leutner, C. Matzhold, L. Bellach, C. Deischinger, J. Harreiter, S. Thurner, P. Klimek, A. Kautzky-Willer, Diagnosis of osteoporosis in statin-treated patients is dose-dependent, Ann Rheum Dis, Epub ahead of print: 26 September 2019

About the Complexity Science Hub Vienna

The CSH Vienna is a joint initiative of the Medical University of Vienna, the TU Wien, the Vienna University of Economics and Business, the Graz University of Technology, the Danube University Krems, the IIASA International Institute for Applied Systems Analysis, the AIT Austrian Institute of Technology, and the Austrian Economic Chambers (WKO).

The mission of the Hub is to host, educate, and inspire complex systems scientists who are dedicated to collecting, handling, aggregating, and making sense of Big Data in ways that are directly valuable for science and society. Scientists at the Hub develop methods for the scientific, quantitative, and predictive understanding of complex systems. Focal areas include the resilience and efficiency of socio-economic and ecological systems, network medicine, the dynamics of innovation, and the science of cities.

About Medical University of Vienna

Medical University Vienna (MedUni Vienna) is one of the most traditional medical education and research facilities in Europe. With almost 8,000 students, it is currently the largest medical training centre in the German-speaking countries. With 5,500 employees, 26 university hospitals and three clinical institutes, 12 medical theory centres and numerous highly specialised laboratories, it is also one of Europe's leading research establishments in the biomedical sector.

Please direct enquiries to:

Mag. Johannes Angerer
Head of Communications and Public Relations, MedUni
Tel.: 0043 1 40 160-11501
Spitalgasse 23, 1090 Vienna

Mag. Thorsten Medwedeff
Communications and Public Relations, MedUni
Tel.: 0043 1 40 160-11505
Spitalgasse 23, 1090 Vienna

Mag.a Verena Ahne
Knowledge Transfer & Dissemination, CSH
Josefstaedter Strasse 39, 1030 Vienna

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.